BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 6293976)

  • 1. The effect of N-formimidoyl thienamycin, ceftazidime, cefotiam, ceftriaxone and cefotaxime on non-fermentative Gram-negative rods, Aeromonas, Plesiomonas and Enterobacter agglomerans.
    von Graevenitz A; Bucher C
    Infection; 1982; 10(5):293-8. PubMed ID: 6293976
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro activity of N-formimidoyl-thienamycin in comparison to that of moxalactam and cefotaxime against gentamicin-resistant gram-negative bacteria.
    Pusztai-Markos Z; Pranada F
    Eur J Clin Microbiol; 1982 Feb; 1(1):49-51. PubMed ID: 6293811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cefoperazone against carbenicillin-resistant isolates of Pseudomonas aeruginosa: comparison with other newer cephalosporins and N-formimidoyl thienamycin.
    Chau PY; Ling J; Ng WS
    J Antimicrob Chemother; 1983 Oct; 12(4):337-45. PubMed ID: 6417100
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activity of N-formimidoyl thienamycin in comparison with cefotaxime, moxalactam, and ceftazidime.
    Verbist L; Verhaegen J
    Antimicrob Agents Chemother; 1981 Mar; 19(3):402-6. PubMed ID: 6264844
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The effect of cefepime on ceftazidime, cefotaxime and imipenem resistant strains of Acinetobacter, Xanthomonas, Pseudomonas, Flavobacterium, Sphingobacterium and on producers of extended spectrum beta-lactamases (ESBL) with resistance transfer].
    Blahová J; Hupková-Lesická M; Králiková K; Krcméry V; Kubonová K
    Cas Lek Cesk; 1997 Mar; 136(5):154-6. PubMed ID: 9221190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Comparative study of ceftriaxone, cefotaxime and moxalactam against 150 Gram negative strains (author's transl)].
    Nasnas R; Gutmann L; Kitzis MD; Goldstein F; Acar JF
    Pathol Biol (Paris); 1982 Jun; 30(6):341-4. PubMed ID: 6287385
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The morphological response of Pseudomonas aeruginosa to azthreonam, cefoperazone, ceftazidime and N-formimidoyl thienamycin.
    Elliott TS; Greenwood D
    J Med Microbiol; 1984 Apr; 17(2):159-69. PubMed ID: 6423826
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of the antibacterial activities of N-formimidoyl thienamycin (MK0787) with those of other recently developed beta-lactam derivatives.
    Cullmann W; Opferkuch W; Stieglitz M; Werkmeister U
    Antimicrob Agents Chemother; 1982 Aug; 22(2):302-7. PubMed ID: 6821459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative in vitro susceptibilities of anaerobic bacteria to cefmenoxime, cefotetan, and N-formimidoyl thienamycin.
    Owens WE; Finegold SM
    Antimicrob Agents Chemother; 1983 Apr; 23(4):626-9. PubMed ID: 6305265
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro activity of ceftazidime and ceftriaxone.
    Keenholtz SL; Jacobus NV; Tally FP; Gorbach SL
    Clin Ther; 1983; 5(6):603-16. PubMed ID: 6313195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Susceptibility of 324 nonfermentative gram-negative rods to 6 cephalosporins and azthreonam.
    Appelbaum PC; Tamim J; Pankuch GA; Aber RC
    Chemotherapy; 1983; 29(5):337-44. PubMed ID: 6311492
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Antibacterial activities of cefotiam against various pathogens isolated from clinical materials (author's transl)].
    Murase M; Niiya T; Katayama Y; Takeuchi N
    Jpn J Antibiot; 1982 Apr; 35(4):1004-8. PubMed ID: 6285018
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of bacterial resistance to the third generation cephalosporins and their clinical use.
    Kolár M; Látal T; Hájek V
    J Chemother; 1999 Aug; 11(4):260-5. PubMed ID: 10465127
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [N-formimidoyl-thienamycin: in vitro activity in bacteria with resistance to beta-lactam antibiotics or gentamicin].
    Bartmann K; Tarbuc R
    Infection; 1982; 10(6):361-70. PubMed ID: 6818153
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activity and beta-lactamase stability of N-formimidoyl thienamycin compared to that of second and third generation cephalosporins.
    Vuye A
    Chemotherapy; 1982; 28(4):267-75. PubMed ID: 6981493
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [In vitro antibacterial activity of a new cephalosporin: cefpirome (HR 810). Comparison with ceftriaxone, cefotaxime, latamoxef and ceftazidime].
    Le Noc P; Bryskier A; Le Noc D
    Pathol Biol (Paris); 1986 Jun; 34(5 Pt 2):567-71. PubMed ID: 3534744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative in-vitro activity of Sch 34343, imipenem, cefpirome and cefotaxime.
    Bauernfeind A
    J Antimicrob Chemother; 1985 Jun; 15 Suppl C():155-64. PubMed ID: 3897170
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibacterial activity of N-formimidoyl thienamycin in comparison with cefotaxime, lamoxactam, cefoperazone, piperacillin gentamicin.
    Braveny I; Machka K; Elsser R
    Infection; 1982 Jan; 10(1):45-9. PubMed ID: 6279523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of ceftazidime and N-formimidoyl thienamycin against gentamicin-susceptible and resistant Pseudomonas aeruginosa.
    Alford RH
    J Antimicrob Chemother; 1983 Jun; 11(6):599-601. PubMed ID: 6411675
    [No Abstract]   [Full Text] [Related]  

  • 20. Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
    Jones RN; Sader HS; Fritsche TR; Pottumarthy S
    Diagn Microbiol Infect Dis; 2007 Jan; 57(1):109-16. PubMed ID: 16930923
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.